Untitled Document
                      Home | Sitemap | Login   
News & Events
Free your Workspace from Colds
Herbal therapy for Sinus
Beef up against the cold and flu
Back to School Blues
Travel without the Sniffles
  Clinical Studies

Common cold

In the year 1999 a study was able to show in patients with a viral respiratory tract infection (ie common cold) that by therapy with Esberitox®N, the complaints were alleviated much faster than under placebo. The duration of the illness was shortened by two days.

H.H. Henneicke-von Zepelin et al.: Efficacy and Safety of a Fixed Combination Phytomedicine in the Treatment of the Common Cold (Acute Viral Respiratory Tract Infection): Results of a Randomised, Double Blind, Placebo Controlled, Multicentre study. Curr Medical Research and Opinion Vol.15 (3), 214-227 (1999)

Use with antibiotic

In the year 2002 a study was done on patients requiring antibiotic because of severe bacterial infection (acute exacerbation of chronic bronchitis). The study shows that recovery is much faster for patients taking Esberitox®N with antibiotic rather than antibiotic by itself. Recovery is seven days faster.



Gert Kohler et al.: Esberitox®N as Supportive Therapy when Providing Standard Antibiotic Treatment in Subjects with a Severe Bacterial Infection (Acute Exacerbation of Chronic Bronchitis). Chemotherapy 48,259-266 (2002)


Clinical trials efficacy
Faster recovery from cold
Concomitant treatment with antibiotic
Use of Esberitox®N in children
Clinical trials conducted with Esberitox®N
Acute and Chronic Respiratory tract infections (of viral or bacterial origin)
Wüstenberg P, Henneicke-von Zepelin HH, Köhler G, Stammwitz U. Adv Ther 1999;16:
Efficacy and mode of action of an immunomodulator herbal preparation
containing echinacea, wild indigo and white cedar.
Henneicke-von Zepelin HH, Hentschel C, Schnitker J, Kohnen R,
Köhler G, Wüstenberg P.
Curr Med Res Opin 1999;15:214–27. Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute viral respiratory
tract infection): results of a randomised, double blind, placebo controlled,
multicentre study.

Naser B, Lund B, Heinneicke-von Zepelin HH, Köhler G, Lehmacher W,
Scaglione F.
Phytomedicine 2005; in press. A randomised double-blind placebo-controlled clinical dose–response trial of an extract of Baptisia/Echinacea and Thuja in the
treatment of patients with common cold.

HD Reitz. Notabene medici (1990) 362-366. Immunomodulators with phytotherapeutic agents.  
MD Vorberg Arztliche Praxis 36 (1984) 97-98. For colds, stimulate the nonspecific immune system  
Accompanying an antibiotics therapy in case of severe bacterial infection
von Blumröder WO. Z Allgemeinmed 1985;61:271–3. Angina lacunaris.  
Hauke W, Köhler G, Henneicke-von Zepelin HH, Freudenstein J. Chemotherapy 2002;48:259–66. Esberitox®N as Supportive therapy when providing standard antibiotic
treatment in subjects with a severe bacterial infection (acute exacerbation
of chronic bronchitis).

M.Zimmer. Therapiewoche (35) (1985), 36: 4024-4028 Specific conservative treatment of acute sinusitis in the ENT practice.  
H.Stolze et al. Der Kassenarzt 23 (1983) 43-38 A treatment with antibiotics can be optimized by additional immunostimulation. (Acute Tonsilitis)  
Leukopenias after radiation or cytostatic treatment
R. Bendel et al. Onkologie 12 (3) 1989, 32-38 Adjuvant therapy with Esberitox®N in patients receiving chemo- and radiation therapy for advanced breast cancer.
Herpes simplex labialis
H. Bockhorst Z allerg. Med. 58 (1982) 1795-1798 The treatment of herpes simplex in practice.
Treatment in children
Kohler et al. Zeitschrift fur Phytotherapie 19 (1998), 318-322 Children’s dosage of phytopharmaceuticals: Representative, Exemplary, Age stratified Dosage practice for Esberitox®N the Herbal combination of active substances.
K.D. Blunck. Kinderartzt 14 (1983), 8:991-992 Susceptibility to infection at children’s home – to increase the resistance against infections.